Recent Developments in licensing
In July 2022, ViiV Healthcare, the manufacturer of cabotegravir, signed a voluntary licensing agreement with the Medicines Patent Pool (MPP). This agreement allows generic manufacturers to produce and supply cabotegravir in 90 low- and middle-income countries.
In March 2023, the MPP signed sublicense agreements with three generic manufacturers: Aurobindo, Cipla, and Viatris. This means that these companies will be able to develop, manufacture, and supply generic versions of cabotegravir in the 90 countries covered by the voluntary licensing agreement.
The development of a generic source of cabotegravir is a major step forward for people living with or at risk of HIV. It will make this important medication more affordable and accessible to people around the world.